News

Mint-Data for Personalized Medicine at Cancer Center in Tübingen/Germany

Compiling structured real-world-data from different medical disciplines, such as molecular genetics, laboratory medicine, pathology or radiology, to generate insights for specific diseases represents the “holy grail” of Personalized Medicine.   The Cancer Center in Tübingen/Germany initiated the project “Structured data in Oncology” focusing on this...

New TNM- and RADS-Classification in mint Lesion

With the aid of various clinical reading templates, mint Lesion provides context-specific support in the application of established radiological criteria and guidelines for a more efficient investigation and documentation of radiological findings. Mint Lesion employs a structured approach to interpreting relevant findings in medical images so...

New mint Lesion 3.4 Software presented at RSNA 2017

With mint Lesion 3.4, reproducible assessment and structured reporting of significant image observations are easier than ever.   Numerous improvements and new functionalities related to the image data handling and display streamline the image assessment. As such, for instance, a refined image series browser provides...

Mint Medical showcases MSK-Prototype at IMR 2017 in Hamburg

Mint Medical was one of the sponsors of the first Intensive course Musculoskeletal Radiology (IMR) which took place on September 8th and 9th 2017 in Hamburg. It was organized by the board of the AG Bildgebende Verfahren des Bewegungsapparats. PD Dr. Marc Regier, its chairman,...

A look ahead with mint Lesion 3.3

Mint Medical is pleased to announce the recent release of their software product version 3.3 of mint LesionTM which was completed during recent weeks. Mint Medical CEO, Dr. Matthias Baumhauer provides his  insight as to what can be expected in this highly anticipated version of...
Kelie Luby

Mrs. Kelie Luby joins Mint Medical’s team

Mrs. Kelie Luby will join Mint Medical’s team from January 2017 as new Vice President Clinical Trials Software and will be introduced at the upcoming RSNA congress in Chicago.   Kelie is an experienced medical scientist and communicator with more than 18 years of clinical...

Novel oncologic therapy response criteria (iRECIST and more)

Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and prediction of treatment response.   At RSNA 2016, Mint Medical showcases a comprehensive set of new criteria including mRECIST mesothelioma, the Lugano (Cheson 2014 lymphoma)…